HRTX Relative Valuation
HRTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HRTX is overvalued; if below, it's undervalued.
Historical Valuation
Heron Therapeutics Inc (HRTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -93.62. The fair price of Heron Therapeutics Inc (HRTX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.31
Fair
-74.86
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Heron Therapeutics Inc. (HRTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.53. The thresholds are as follows: Strongly Undervalued below -17.05, Undervalued between -17.05 and -9.79, Fairly Valued between 4.73 and -9.79, Overvalued between 4.73 and 11.99, and Strongly Overvalued above 11.99. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
67.07
EV/EBIT
Heron Therapeutics Inc. (HRTX) has a current EV/EBIT of 67.07. The 5-year average EV/EBIT is -78.99. The thresholds are as follows: Strongly Undervalued below -1655.76, Undervalued between -1655.76 and -867.37, Fairly Valued between 709.39 and -867.37, Overvalued between 709.39 and 1497.77, and Strongly Overvalued above 1497.77. The current Forward EV/EBIT of 67.07 falls within the Historic Trend Line -Fairly Valued range.
1.39
PS
Heron Therapeutics Inc. (HRTX) has a current PS of 1.39. The 5-year average PS is 4.33. The thresholds are as follows: Strongly Undervalued below -4.09, Undervalued between -4.09 and 0.12, Fairly Valued between 8.54 and 0.12, Overvalued between 8.54 and 12.75, and Strongly Overvalued above 12.75. The current Forward PS of 1.39 falls within the Historic Trend Line -Fairly Valued range.
64.69
P/OCF
Heron Therapeutics Inc. (HRTX) has a current P/OCF of 64.69. The 5-year average P/OCF is -3.24. The thresholds are as follows: Strongly Undervalued below -54.34, Undervalued between -54.34 and -28.79, Fairly Valued between 22.31 and -28.79, Overvalued between 22.31 and 47.86, and Strongly Overvalued above 47.86. The current Forward P/OCF of 64.69 falls within the Strongly Overvalued range.
0.00
P/FCF
Heron Therapeutics Inc. (HRTX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.24. The thresholds are as follows: Strongly Undervalued below -33.23, Undervalued between -33.23 and -16.50, Fairly Valued between 16.98 and -16.50, Overvalued between 16.98 and 33.72, and Strongly Overvalued above 33.72. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Heron Therapeutics Inc (HRTX) has a current Price-to-Book (P/B) ratio of 34.20. Compared to its 3-year average P/B ratio of -3.84 , the current P/B ratio is approximately -990.11% higher. Relative to its 5-year average P/B ratio of 0.47, the current P/B ratio is about 7158.82% higher. Heron Therapeutics Inc (HRTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -29.71%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -28.79% , the current FCF yield is about -100.00% lower.
34.20
P/B
Median3y
-3.84
Median5y
0.47
-13.37
FCF Yield
Median3y
-29.71
Median5y
-28.79
Competitors Valuation Multiple
The average P/S ratio for HRTX's competitors is 0.00, providing a benchmark for relative valuation. Heron Therapeutics Inc Corp (HRTX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 16.47%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HRTX decreased by 14.38% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -14.78 to -45.78.
The secondary factor is the Revenue Growth, contributed 16.47%to the performance.
Overall, the performance of HRTX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Heron Therapeutics Inc (HRTX) currently overvalued or undervalued?
What is Heron Therapeutics Inc (HRTX) fair value?
How does HRTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Heron Therapeutics Inc (HRTX) as of Dec 05 2025?
What is the current FCF Yield for Heron Therapeutics Inc (HRTX) as of Dec 05 2025?
What is the current Forward P/E ratio for Heron Therapeutics Inc (HRTX) as of Dec 05 2025?